Ernest Beasley, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1467562959
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 805 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations.
Across 805 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Amgen$1K
- Sanofi-aventis U.S. LLC$1K
- IBSA Pharma Inc.$832
- Tandem Diabetes Care, Inc.$620
- plus $6K from 42 others
What the payments were for
- Food & beverage$14,296100%
- Education$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$14,354 in reported general payments places this provider in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 134 | $227,373 |
| JardianceEmpagliflozin | 80 | $106,877 |
| JanuviaSitagliptin Phosphate | 68 | $79,551 |
| FarxigaDapagliflozin Propanediol | 40 | $63,632 |
| SynthroidLevothyroxine Sodium | 456 | $53,230 |
| ProliaDenosumab | 27 | $46,327 |
| JanumetSitagliptin Phos/Metformin Hcl | 33 | $41,749 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 64 | $40,380 |
| MounjaroTirzepatide | 29 | $38,476 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $27,011 |
| TrulicityDulaglutide | 19 | $26,973 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 126 | $26,765 |
| Humalog Kwikpen U-100Insulin Lispro | 61 | $22,210 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $16,979 |
| Novolog FlexpenInsulin Aspart | 43 | $13,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $2,186 | $237,206158 claims |
| MerckJanuvia, Janumet | $279 | $121,300101 claims |
| Boehringer IngelheimJardiance | $504 | $106,87780 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,871 | $73,69694 claims |
| AstraZenecaFarxiga | $354 | $63,63240 claims |
| AbbVieSynthroid | $584 | $53,230456 claims |
| AmgenProlia | $1,330 | $46,32727 claims |
| Alvogen IncTeriparatide | $23 | $12,00512 claims |
| Sanofi-aventis U.S. LLCLantus | $1,040 | $8,37042 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $477 | $6,142441 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Jonathan OwnbyAtlanta$291K
- Gulliermo UmpierrezAtlanta$63K
- Francisco PasquelAtlanta$40K
- Norman WelchAtlanta$25K
- Rachel DerrAtlanta$18K
- Kate WheelerAtlanta$17K
- John ZoraAtlanta$16K
- Era ShahAtlanta$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.